C4 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	130.03	33.03	79.4	184.3	93.13	38.89
Short-Term Investments	127.09	246.4	233.16	189.96	0	0
Cash & Cash Equivalents	257.12	279.43	312.56	374.27	93.13	38.89
Cash Growth	-7.98%	-10.60%	-16.49%	301.89%	139.47%	-
Receivables	11.8	1.47	5.72	4.48	4.62	86.44
Other Current Assets	2.27	6.65	7.42	2.26	-0.98	-1.8
Total Current Assets	271.19	287.56	325.69	381.01	96.77	123.53
Property, Plant & Equipment	71.09	77.52	35.05	16.55	18.92	20.38
Long-Term Investments	28.01	60.96	142.2	0	0	0
Other Long-Term Assets	6.17	4.81	3.82	2.58	2.58	2.58
Total Long-Term Assets	105.26	143.28	181.08	19.13	21.49	22.96
Total Assets	376.45	430.84	506.77	400.14	118.26	146.49
Accounts Payable	1.45	1.17	4.51	5.68	5.39	1.15
Deferred Revenue	37.29	33.51	56.17	81.22	93.42	96.66
Current Debt	5.22	6.99	1.33	1.04	0.88	0.73
Other Current Liabilities	-1.18	2.87	-10.76	-44.09	-66.05	-74.6
Total Current Liabilities	42.77	44.55	51.25	43.85	33.64	23.95
Long-Term Debt	65.76	80.17	41.55	21.88	12.87	13.75
Other Long-Term Liabilities	21.81	16.9	24.37	53.62	72.72	77.55
Total Long-Term Liabilities	87.57	97.06	65.91	75.5	85.59	91.3
Total Liabilities	130.34	141.61	117.16	119.35	119.23	115.25
Total Debt	70.98	87.15	42.88	22.92	13.75	14.48
Debt Growth	-18.56%	103.25%	87.08%	66.70%	-5.06%	-
Retained Earnings	-528.38	-395.89	-267.72	-183.82	-117.49	-83.39
Comprehensive Income	-0.13	-4.14	-0.78	0.01	0	0
Shareholders' Equity	246.11	289.23	389.61	280.79	-111.96	-79.75
Net Cash / Debt	186.15	192.28	269.68	351.35	79.38	24.41
Net Cash / Debt Growth	-3.19%	-28.70%	-23.24%	342.63%	225.24%	-
Net Cash Per Share	3.75	3.94	5.86	30.90	57.86	2.24
Working Capital	228.42	243.01	274.44	337.16	63.13	99.58
Book Value Per Share	4.96	5.92	8.46	24.70	-81.61	-7.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).